A61P 11 - Drugs for disorders of the respiratory system

Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2002
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083167A2 Therapeutic compositions for the treatment of a respiratory tract disease
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	WO2002083113A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
10/24/2002	WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	WO2002083079A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
10/24/2002	WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors
10/24/2002	WO2002061998A3 Access parameter adaptation and packet data resource management using detailed mobile status information
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002047667A3 Novel medicament compositions based on anticholinesterase drugs and on a steroid
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2002013825A8 Novel pharmaceutical use of quinnoline derivatives
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001072315A9 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	US20020156269 Crystals of diuridine tetraphosphate or salt thereof, process for producing the crystals, and process for producing the compounds
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156099 1-acyl-piperidine substance p antagonist; used to treat central nervous system disorders and respiratory diseases
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156053 Treating gastro-oesophageal reflux disease
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156013 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155992 Paclitaxel, epipodophyllotoxin, decetaxel, topotecan, and podophyllotoxin covalently conjugated to a polypeptide drug carrier having 50-90% by weight glutamic acid; inproved solubility
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155150 Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155094 Method of treating sepsis and ARDS using chemokine beta-9
10/24/2002	US20020155067 For drug delivery
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443777A1 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2443107A1 Therapeutic compositions for the treatment of a respiratory tract disease
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1251171A1 Novel endoplasmic reticulum-localized protein, remedies containing the same for diseases associated with glycoprotein abnormality, dna encoding this protein and gene remedies containing the same for treating diseases associated with glycoprotein abnormality
10/23/2002	EP1250343A1 Azalide antibiotic compositions
10/23/2002	EP1250332A1 Inhibitors of interleukin 5 gene expression
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250313A1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1150702B1 Use of orosomucoid for the production of a pharmaceutical preparation for the treatment of pancreatitis
10/23/2002	EP0923561B1 Heterocyclic metalloprotease inhibitors
10/23/2002	EP0883681B1 Conjugated linoleic acids for attenuating the allergic response
10/23/2002	CN1376165A Materials and methods for inhibition of Lg E production
10/23/2002	CN1376160A Novel macrolide antibiotics
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376069A Methods and compositions for reducing sympathomimetic-induced side effects
10/23/2002	CN1376065A Compositions having improved stability
10/23/2002	CN1376063A Cyclic amine CCR3 antagonisis
10/23/2002	CN1376054A Topcial suspension formulations containing ciprofloxacin and dexa methasone
10/23/2002	CN1376036A Metal-containing compositions, preparations and uses
10/23/2002	CN1375331A Antiphlogistic capsule capable of keeping the adverse energy downwards
10/23/2002	CN1375314A Fermented soybean extracted liquid and composite medicine containing the said liquid
10/23/2002	CN1092983C Lidan (leopard cat gall) lozerge
10/23/2002	CN1092975C Cough relieving oral medicine
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469025 For the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role; inhibiting the binding of alpha 4 integrins to their ligands
10/22/2002	US6469018 Compounds
10/22/2002	US6469013 Therapeutic compounds
10/22/2002	US6469011 Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6469001 IL-5 inhibiting 6-azauracil derivatives
10/22/2002	US6469000 1,3-diheterocyclic metalloprotease inhibitors
10/22/2002	US6468994 Budesonide particles and pharmaceutical compositions containing them
10/22/2002	US6468798 Liposome-nucleic acid complexes are prepared then delivered via aerosol to the lung airway; for transforming pulmonary cells and treating lung diseases
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/17/2002	WO2002081668A2 Desaturase genes and uses thereof
10/17/2002	WO2002081521A2 Osteoprotegerin in milk
10/17/2002	WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	WO2002081507A2 Interferon gamma polypeptide variants

1 ... 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 ... 878